ARTV · Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics announced Q1 2026 financial results showing increased R&D expenses to $19.3 million from $17.1 million year-over-year, driven by ongoing clinical development of AlloNK, leading to a net loss of $23.5 million versus $20.3 million in Q1 2025. Cash position stood at $86.8 million as of March 31, 2026, sufficient to fund operations into Q2 2027, providing visibility amid advancing the lead program. The quarter's highlight was positive initial clinical data from ongoing trials of AlloNK (AB-101) plus rituximab in B-cell driven autoimmune diseases, with pooled data as of April 3, 2026, showing 71% ACR50 response in seven refractory RA patients with six months follow-up in the company-sponsored Phase 2a basket trial. Across 21 RA patients, 19 showed clinically meaningful reductions in CDAI (mean 37 points at six months) and DAS28-ESR (mean 2.8 points), with no relapses or new b/tsDMARD starts. Safety profile supported outpatient administration, with no CRS or ICANS, no AlloNK-related serious AEs, and low infection rates comparable to approved RA therapies. FDA alignment on a Phase 3 registrational trial design in refractory RA patients failing two or more b/tsDMARD classes marks a critical milestone, with 2:1 randomization to AlloNK plus rituximab versus rituximab alone, ACR50 at six months as primary endpoint, planned initiation in H2 2026. Over 70 patients treated across >40 sites, mostly community settings, bolsters infrastructure for the global Phase 3 across >80 sites. Suspension of ATM offering reflects capital management, with $86.8M cash supporting key milestones like EULAR 2026 presentations and trial start.